Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
AN2 Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, between the Company, Cowen and Company, LLC, Leerink Partners LLC and Evercore Group L.L.C.",
"Opinion of Cooley LLP",
"AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock Menlo Park, CA - August 15, 2023 - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares of common stock are being sold at a price of $9.00 per share, a premium from today's closing price. Investors who have agreed to purchase shares in the offering include RA Capital Management, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital Partners LP, Avidity Partners, Janus Henderson Investors and Surveyor Capital . The gross proceeds from the offering to AN2 are expected to be..."
08/10/2023 8-K Quarterly results
Docs: "AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September Menlo Park, CA – August 10, 2023 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. “We’re pleased with the accelerated pace of enrollment in our pivotal Phase 2/3 study evaluating epetraborole for treatment-refractory MAC lung disease and b..."
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex lung disease Menlo Park, CA – May 11, 2023 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2023. “In the first quarter we continued to advance our pivotal Phase 2/3 trial evaluating epetraborole for treatment-refractory MAC lung disease with a total of nearly 80 clinical sites active worldwide. We are pleased with the momentum we’re seeing in the Asia-Pacific region, particula..."
03/29/2023 8-K Quarterly results
11/09/2022 8-K Quarterly results
Docs: "AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates • U.S. Enrollment Ongoing in EBO-301 Pivotal Phase 2/3 Clinical Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Plan to Include Japanese Patients in Trial • Awarded Contract from NIAID Valued Up to $17.8 Million to Advance Development of Epetraborole for Acute Systemic Melioidosis Menlo Park, CA – November 9, 2022 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2022. “Chronic lung infections, such as Mycobacterium avium complex lung disease, are debilitating and can be..."
10/06/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
Docs: "AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates • Enrolling U.S. Patients in the EBO-301 Pivotal Phase 2/3 Trial of Epetraborole in Treatment-Refractory MAC Lung Disease; Topline Results from Phase 2 Part of Trial Expected in Mid-2023 • Completed Enrollment in Phase 1 PK/Safety Study of Epetraborole in Healthy Volunteers in Japan • Plan to Include Japanese Patients in EBO-301 Pivotal Phase 2/3 Trial; Gained Alignment with the PMDA on the Use of a Microbiological Primary Endpoint to Support Potential Registration in Japan Menlo Park, CA – August 11, 2022 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet need..."
06/29/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease"
05/10/2022 8-K Quarterly results
Docs: "AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates • On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering • Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Begin in First Half of 2022 • AN2 Board Strengthened through Appointment of Key Industry Executives Menlo Park, CA – May 10, 2022 – AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2022. “Over the past several mon..."
05/09/2022 8-K Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 5, 2022 AN2 THERAPEUTICS, INC. Delaware 001-41331 82-0606654 1800 El Camino Real, Suite D Menlo Park, California 94027 Registrant's Telephone Number, Including Area Code: 331-9090 N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comme...",
"AN2 Therapeutics Appoints Maggie FitzPatrick to its Board of Directors"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy